Compared efficacy of rituximab, abatacept, and tocilizumab in patients with rheumatoid arthritis refractory to methotrexate or TNF inhibitors agents: a systematic review and network meta-analysis

[1] Scott DL(2010)Rheumatoid arthritis Lancet 376 1094-1108

[2] Wolfe F(2007)Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study Arthritis Rheum 56 13-20

[3] Huizinga TW(2008)Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results Ann Rheum Dis 67 402-408

[4] Hyrich KL(2002)Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion Arthritis Rheum 46 1470-1479

[5] Lunt M(2014)Continued benefit of tocilizumab plus disease-modifying antirheumatic drug therapy in patients with rheumatoid arthritis and inadequate clinical responses by week 8 of treatment J Rheumatol 41 216-226

[6] Watson KD(2011)Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis Ann Rheum Dis 70 266-271

[7] Symmons DP(2010)Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs Semin Arthritis Rheum 39 425-441

[8] Silman AJ(2012)Comparative effectiveness and safety of biological treatment options after tumour necrosis factor α inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis Ann Rheum Dis 71 1303-1308

[9] Kavanaugh A(2016)Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation Health Technol Assess 20 1-610

[10] Rosengren S(2011)Adverse effects of biologics: a network meta-analysis and Cochrane overview Cochrane Database Syst Rev 2011 CD008794-1588

[1] Scott DL(2010)Rheumatoid arthritis Lancet 376 1094-1108

[2] Wolfe F(2007)Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study Arthritis Rheum 56 13-20

[3] Huizinga TW(2008)Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results Ann Rheum Dis 67 402-408

[4] Hyrich KL(2002)Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion Arthritis Rheum 46 1470-1479

[5] Lunt M(2014)Continued benefit of tocilizumab plus disease-modifying antirheumatic drug therapy in patients with rheumatoid arthritis and inadequate clinical responses by week 8 of treatment J Rheumatol 41 216-226

[6] Watson KD(2011)Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis Ann Rheum Dis 70 266-271

[7] Symmons DP(2010)Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs Semin Arthritis Rheum 39 425-441

[8] Silman AJ(2012)Comparative effectiveness and safety of biological treatment options after tumour necrosis factor α inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis Ann Rheum Dis 71 1303-1308

[9] Kavanaugh A(2016)Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation Health Technol Assess 20 1-610

[10] Rosengren S(2011)Adverse effects of biologics: a network meta-analysis and Cochrane overview Cochrane Database Syst Rev 2011 CD008794-1588